{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:50:21Z","timestamp":1790423421758,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T00:00:00Z","timestamp":1205107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec><jats:title>AIMS<\/jats:title><jats:p>To evaluate the pharmacokinetics, safety and tolerability of single and multiple oral doses of maraviroc in healthy volunteers.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Three double\u2010blind, placebo\u2010controlled, dose\u2010escalation studies with either single or multiple doses of maraviroc were conducted in healthy volunteers. Plasma and urine samples were collected to investigate the pharmacokinetics of maraviroc and evaluate any changes with respect to dose and duration\/frequency of dosing. Safety and toleration of maraviroc were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Maraviroc is rapidly absorbed following oral administration, and plasma <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub> is achieved within 0.5\u20134.0\u2003h postdose. Steady\u2010state plasma concentrations are achieved after 7 consecutive days of dosing. Although the pharmacokinetics of maraviroc is nonproportional over the dose range studied (3\u20131200\u2003mg), the degree of nonproportionality is small at clinically relevant doses. Renal clearance is approximately 10\u201312\u2003l\u2003h<jats:sup>\u22121<\/jats:sup> and appears unaffected by increasing maraviroc doses. Maraviroc does not significantly modulate the activity of CYP2D6 or CYP3A4 at clinically relevant doses. There were no serious adverse events in any of these studies, and doses up to 900\u2003mg were generally well tolerated, with postural hypotension being the dose\u2010limiting event. There was no pattern or dose relationship observed with maraviroc with regard to laboratory abnormalities, including hepatic transaminases. No clinically significant increases in QTc were noted at clinically relevant doses.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Maraviroc is absorbed into the systemic circulation and reaches steady state by day 7 of multiple dosing. It does not significantly influence the activity of major drug\u2010metabolizing enzymes and is well tolerated at clinically relevant doses, with most adverse events being mild or moderate.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2008.03130.x","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T04:04:35Z","timestamp":1205208275000},"page":"5-18","source":"Crossref","is-referenced-by-count":75,"title":["Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers"],"prefix":"10.1111","volume":"65","author":[{"given":"Samantha","family":"Abel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elna","family":"Van Der Ryst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Ridgway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine G.","family":"Medhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Taylor\u2010Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Muirhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,10]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"AIDS Epidemic Update: Special Report on HIV\/AIDS.","author":"Joint United Nations Programme on HIV\/AIDS.","year":"2006"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2460924"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2479983"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1196-1240"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199807010-00005"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/507312"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4721-4732.2005"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002626"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1319"},{"key":"e_1_2_6_11_2","unstructured":"LalezariJ GoodrichJ DeJesusE LampirisH GulickR SaagM RidgwayC McHaleM Van Der RystE MayerH. Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viremic antiretroviral treatment experienced patients infected with CCR5\u2010tropic HIV\u20101: 24\u2010week results of a phase 2b\/3 study in the USA and Canada. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007 February 25\u201328; Los Angeles CA."},{"key":"e_1_2_6_12_2","unstructured":"NelsonM F\u00e4tkenheuerG KonourinaI LazzarinA ClumeckN HorbanA TawadrousM SullivanJ MayerH Van Der RystE. Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viremic antiretroviral treatment experienced patients infected with CCR5\u2010tropic (R5) HIV\u20101 in Europe Australia and North America: 24\u2010week results. In: 14th Conference on Retroviruses and Opportunistic Infections; 2007 February 25\u201328; Los Angeles CA."},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","unstructured":"RosarioMC JacqminP DorrP JamesI JenkinsTM AbelS Van Der RystE.Population pharmacokinetic\u2010pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV\u2010positive patients.Br J Clin Pharmacol2008;65(Suppl. 1):86\u201394.","DOI":"10.1111\/j.1365-2125.2008.03140.x"},{"key":"e_1_2_6_14_2","unstructured":"AyoubA Van der RystE TurnerK McHaleM.A review of the markers of immune function during the maraviroc phase I and IIa studies (abstract 509). In: 14th Conference on Retroviruses and Opportunistic Infections; 2007 February 25\u201328; Los Angeles CA."},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","unstructured":"DavisJ HackmanF LaytonG HigginsT SudworthD WeissgerberG.The effect of single doses of maraviroc on the QT\/QTc interval in healthy subjects.Br J Clin Pharmacol2008;65(Suppl. 1):68\u201375.","DOI":"10.1111\/j.1365-2125.2008.03138.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","unstructured":"ChanPLS WeatherleyB McFadyenL.A population pharmacokinetic meta\u2010analysis of maraviroc in healthy volunteers and asymptomatic HIV\u2010infected subjects.Br J Clin Pharmacol2008;65(Suppl. 1):76\u201385.","DOI":"10.1111\/j.1365-2125.2008.03139.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250110052779"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","unstructured":"AbelS RussellD WhitlockLA RidgwayCE MuirheadGJ.Effect of maraviroc on the pharmacokinetics of midazolam lamivudine\/zidovudine and ethinyloestradiol\/levonorgestrel in healthy volunteers.Br J Clin Pharmacol2008;65(Suppl. 1):19\u201326.","DOI":"10.1111\/j.1365-2125.2008.03132.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/heart.87.3.220"},{"key":"e_1_2_6_20_2","unstructured":"RussellD BakhtyariA JazrawiRP WhitlockL RidgwayC McHaleM et\u2003al.Multiple dose study to investigate the safety of UK\u2010427\u2003857 (100 mg or 300 mg) BID for 28\u2003days in healthy males and females. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14\u201317; Chicago IL."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03130.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03130.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:27:11Z","timestamp":1694615231000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03130.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,10]]},"references-count":19,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03130.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03130.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,10]]}}}